# Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy

> **NCT04483700** · PHASE3 · WITHDRAWN · sponsor: **Gilead Sciences**

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **DRUG:** Filgotinib
- **DRUG:** Placebo to Match Filgotinib

## Key facts

- **NCT ID:** NCT04483700
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-12
- **Primary completion:** 2022-10
- **Final completion:** 2024-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Development program terminated
- **Last updated:** 2021-01-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04483700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04483700, "Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04483700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*